A Meta-analysis of the Effect of Thiazolidinediones on Blood Pressure

Overview

Journal J Clin Hypertens (Greenwich)

Specialty Cardiology & Vascular Diseases

Date 2006 Jan 13

PMID 16407685

Citations 22

Authors

Rehan Qayyum

Jurga Adomaityte

Affiliations

Soon will be listed here.

Abstract

In epidemiologic studies, insulin resistance is associated with hypertension. Thiazolidinediones (TZDs) are antidiabetic agents that decrease insulin resistance. Multiple clinical trials have evaluated the effect of TZDs on blood pressure (BP) with inconsistent results. The aim of this study was to estimate the effect of TZDs on BP. The authors searched PubMed for clinical trials published in English. A total of 37 clinical trials that reported a change in BP were included in the analysis. Trials with independent-group design and trials with pre-post design were evaluated separately. When compared with baseline, TZDs lowered systolic BP by 4.70 mm Hg (95% confidence interval, -6.13 to -3.27) and diastolic BP by 3.79 mm Hg (95% confidence interval, -5.82 to -1.77). When compared with placebo, TZDs lowered systolic BP by 3.47 mm Hg (95% confidence interval, -4.91 to -2.02) and diastolic BP by 1.84 mm Hg (95% confidence interval, -3.43 to -0.25). Thus, TZDs lower both systolic and diastolic BP, albeit the BP-lowering effect is small and may not be of clinical significance.

Citing Articles

The Many Facets of PPAR-γ Agonism in Obesity and Associated Comorbidities: Benefits, Risks, Challenges, and Future Directions.

Kounatidis D, Vallianou N, Rebelos E, Kouveletsou M, Kontrafouri P, Eleftheriadou I Curr Obes Rep. 2025; 14(1):19.

PMID: 39934485 DOI: 10.1007/s13679-025-00612-4.

Is fluid retention a cardiovascular risk factor?.

Blankfield R Clin Hemorheol Microcirc. 2024; 88(2):277-288.

PMID: 39302357 PMC: 11492017. DOI: 10.3233/CH-242128.

[Individualising antihypertensive therapy in patients with diabetes. A guideline by the Austrian Diabetes Association (update 2023)].

Saely C, Schernthaner G, Brix J, Klauser-Braun R, Zitt E, Drexel H Wien Klin Wochenschr. 2023; 135(Suppl 1):147-156.

PMID: 37101036 PMC: 10133364. DOI: 10.1007/s00508-023-02189-1.

Pioglitazone in diabetic kidney disease: forgotten but not gone.

Papaetis G Arch Med Sci Atheroscler Dis. 2022; 7:e78-e93.

PMID: 36158067 PMC: 9487837. DOI: 10.5114/amsad/151046.

Salt-Sensitivity of Blood Pressure and Insulin Resistance.

Ertuglu L, Elijovich F, Laffer C, Kirabo A Front Physiol. 2021; 12:793924.

PMID: 34966295 PMC: 8711096. DOI: 10.3389/fphys.2021.793924.

References

Honisett S, Stojanovska L, Sudhir K, Kingwell B, Dawood T, Komesaroff P . Rosiglitazone lowers blood pressure and increases arterial compliance in postmenopausal women with type 2 diabetes. Diabetes Care. 2003; 26(11):3194-5. DOI: 10.2337/diacare.26.11.3194. View

Kerenyi Z, Samer H, James R, Yan Y, Stewart M . Combination therapy with rosiglitazone and glibenclamide compared with upward titration of glibenclamide alone in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract. 2004; 63(3):213-23. DOI: 10.1016/j.diabres.2003.09.009. View

Desvergne B, Wahli W . Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev. 1999; 20(5):649-88. DOI: 10.1210/edrv.20.5.0380. View

Charbonnel B, Dormandy J, Erdmann E, Massi-Benedetti M, Skene A . The prospective pioglitazone clinical trial in macrovascular events (PROactive): can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5238 patients. Diabetes Care. 2004; 27(7):1647-53. DOI: 10.2337/diacare.27.7.1647. View

Lin S, Lin Y, Kuo S, Hsu Y, Hung Y . Rosiglitazone improves glucose metabolism in nondiabetic uremic patients on CAPD. Am J Kidney Dis. 2003; 42(4):774-80. DOI: 10.1016/s0272-6386(03)00844-8. View

Shargorodsky M, Wainstein J, Gavish D, Leibovitz E, Matas Z, Zimlichman R . Treatment with rosiglitazone reduces hyperinsulinemia and improves arterial elasticity in patients with type 2 diabetes mellitus. Am J Hypertens. 2003; 16(8):617-22. DOI: 10.1016/s0895-7061(03)00911-7. View

Hsueh W, Bruemmer D . Peroxisome proliferator-activated receptor gamma: implications for cardiovascular disease. Hypertension. 2004; 43(2):297-305. DOI: 10.1161/01.HYP.0000113626.76571.5b. View

Yosefy C, Magen E, Kiselevich A, Priluk R, London D, Volchek L . Rosiglitazone improves, while Glibenclamide worsens blood pressure control in treated hypertensive diabetic and dyslipidemic subjects via modulation of insulin resistance and sympathetic activity. J Cardiovasc Pharmacol. 2004; 44(2):215-22. DOI: 10.1097/00005344-200408000-00011. View

Nakamura T, Ushiyama C, Osada S, Hara M, Shimada N, Koide H . Pioglitazone reduces urinary podocyte excretion in type 2 diabetes patients with microalbuminuria. Metabolism. 2001; 50(10):1193-6. DOI: 10.1053/meta.2001.26703. View

10.

Hung Y, Hsieh C, Pei D, Kuo S, Lee J, Wu L . Rosiglitazone improves insulin sensitivity and glucose tolerance in subjects with impaired glucose tolerance. Clin Endocrinol (Oxf). 2005; 62(1):85-91. DOI: 10.1111/j.1365-2265.2004.02178.x. View

11.

Negro R, Mangieri T, Dazzi D, Pezzarossa A, Hassan H . Rosiglitazone effects on blood pressure and metabolic parameters in nondipper diabetic patients. Diabetes Res Clin Pract. 2005; 70(1):20-5. DOI: 10.1016/j.diabres.2005.02.012. View

12.

Carr A, Workman C, Carey D, Rogers G, Martin A, Baker D . No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, double-blind, placebo-controlled trial. Lancet. 2004; 363(9407):429-38. DOI: 10.1016/S0140-6736(04)15489-5. View

13.

REYNOLDS L, Konz E, Frederich R, Anderson J . Rosiglitazone amplifies the benefits of lifestyle intervention measures in long-standing type 2 diabetes mellitus. Diabetes Obes Metab. 2002; 4(4):270-5. DOI: 10.1046/j.1463-1326.2002.00207.x. View

14.

Rajagopalan R, Iyer S, Khan M . Effect of pioglitazone on metabolic syndrome risk factors: results of double-blind, multicenter, randomized clinical trials. Curr Med Res Opin. 2005; 21(1):163-72. DOI: 10.1185/030079904x20295. View

15.

Fukunaga Y, Itoh H, Doi K, Tanaka T, Yamashita J, CHUN T . Thiazolidinediones, peroxisome proliferator-activated receptor gamma agonists, regulate endothelial cell growth and secretion of vasoactive peptides. Atherosclerosis. 2001; 158(1):113-9. DOI: 10.1016/s0021-9150(01)00430-0. View

16.

Sarafidis P, Lasaridis A, Nilsson P, Pagkalos E, Hitoglou-Makedou A, Pliakos C . Ambulatory blood pressure reduction after rosiglitazone treatment in patients with type 2 diabetes and hypertension correlates with insulin sensitivity increase. J Hypertens. 2004; 22(9):1769-77. DOI: 10.1097/00004872-200409000-00022. View

17.

Haffner S . Epidemiology of hypertension and insulin resistance syndrome. J Hypertens Suppl. 1997; 15(1):S25-30. DOI: 10.1097/00004872-199715011-00003. View

18.

Wu L, Wang R, de Champlain J, Wilson T . Beneficial and deleterious effects of rosiglitazone on hypertension development in spontaneously hypertensive rats. Am J Hypertens. 2004; 17(9):749-56. DOI: 10.1016/j.amjhyper.2004.04.010. View

19.

Nakamura T, Ushiyama C, Shimada N, Hayashi K, Ebihara I, Koide H . Comparative effects of pioglitazone, glibenclamide, and voglibose on urinary endothelin-1 and albumin excretion in diabetes patients. J Diabetes Complications. 2000; 14(5):250-4. DOI: 10.1016/s1056-8727(00)00124-0. View

20.

St John Sutton M, Rendell M, Dandona P, Dole J, Murphy K, Patwardhan R . A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes. Diabetes Care. 2002; 25(11):2058-64. DOI: 10.2337/diacare.25.11.2058. View